Tenacia Biotechnology
Updated: March 12, 2026
CEO - Xiaoxiang Chen
Country: China | Funding: $308M (+)
Founded: 2022
Website: https://www.tenacia.com/en/
Rapport Therapeutics develops drugs for the treatment of central nervous system disorders. Its lead asset RAP-219 is designed for the treatment of focal epileptic seizures and primary generalized tonic-clonic seizures. It's a potential first-in-class negative allosteric modulator of the AMPA receptor, specific for TARPγ8. RAP-219 has multiple indications, including focal epilepsy and acute mania in bipolar disorder, as well as an anticonvulsant. The company has secured development and commercialization rights for its lead drug in Greater China.
Founded: 2022
Website: https://www.tenacia.com/en/
Rapport Therapeutics develops drugs for the treatment of central nervous system disorders. Its lead asset RAP-219 is designed for the treatment of focal epileptic seizures and primary generalized tonic-clonic seizures. It's a potential first-in-class negative allosteric modulator of the AMPA receptor, specific for TARPγ8. RAP-219 has multiple indications, including focal epilepsy and acute mania in bipolar disorder, as well as an anticonvulsant. The company has secured development and commercialization rights for its lead drug in Greater China.
